License Growth Drives Tableau Software (DATA) to 3Q Revenue Beat; Wedbush Reiterates Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Tableau Software (DATA) PT Raised to $132 at Drexel Hamilton
November 6, 2015 8:21 AM ESTDrexel Hamilton analyst Brian White reiterated a Buy rating and raised his price target on Tableau Software (NYSE: DATA) to $132.00 (from $120.00) following big upside in Q3.
In addition to the usual quarterly run through Brian White from Drexel Hamilton noted that Tableau... More
Good Tableau Software (DATA) Quarter but Spending Will Keep Dragging Down Margins - FBR
November 6, 2015 7:26 AM ESTTableau Software (NYSE: DATA) total revenue of $170.8 million (64% year over year) handily beat the Street's estimate of $157.6 million. License revenue came in at $109.5 million, which represented 57% yearover-year growth (versus 60% growth in 2Q) above the Street's estimate of $101.5 million. The better than expected top line and margins flowed through to EPS of $0.15 which beat the... More
After-Hours Movers 11/05: (DATA) (WTW) (QRVO) Higher; (KBIO) (MW) (GLUU) Lower (more...)
November 5, 2015 6:17 PM ESTKaloBios Pharma (NASDAQ: KBIO) 32.6% LOWER; announced that it will reduce its workforce as part of a plan to reduce operating costs. This action will reduce the company's workforce by approximately 17 employees (or 61%), and will focus the company's resources on the ongoing development of lenzilumab, also known as KB003, in chronic monomyelocytic leukemia (CMML), while it continues to pursue strategic alternatives for the company.
The Men's Wearhouse (NYSE: MW) 28% LOWER; the Company now expects adjusted EPS to be in the... More
Tableau Software (DATA) Tops Q3 EPS by 7c
November 5, 2015 4:02 PM ESTTableau Software (NYSE: DATA) reported Q3 EPS of $0.14, $0.07 better than the analyst estimate of $0.07. Revenue for the quarter came in at $170.8 million versus the consensus estimate of $157.62 million.
For earnings history and earnings-related data on Tableau Software (DATA) click here.
... MoreTrading Radar for 11/5: Disney (DIS), Celgene (CELG), SeaWorld (SEAS), Sprouts (SFM), CyberArk (CYBR) Report
November 4, 2015 3:11 PM ESTThe Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Economics:
8:30am EDT
Earnings:
A.M. Castle & Co. (NYSE: CAS) - no Street consensus
ACI Worldwide, Inc. (Nasdaq: ACIW) - consensus EPS $0.11
AES Corp (NYSE: AES) - consensus EPS $0.38
ANSYS... More

